The long-term objective of this project is to elucidate the relationships among dengue virus (DENV)-specific immune responses measured before and during acute infection, DENV-specific immune responses induced by a tetravalent live-attenuated vaccine, and the clinical outcome of infection. The adaptive immune response to DENV has the potential for either positive (protective) or negative (pathologic) effects on subsequent DENV infection. We hypothesize that quantitative, qualitative, and kinetic aspects of DENVspecific immune responses all play important roles in determining the outcome of infection, and that these features of DENV-specific immunity depend on the sequence and frequency of exposure to DENV. We will address our hypotheses through the following Specific Aims: 1. Define immunodominant T cell epitopes associated with secondary DENV infection and specific HLA alleles and sequences of infection 2. Define the relationships between pre-infection DENV-specific immune responses, immune activation during infection, and clinical outcome 3. Define the relationships between pre-existing DENV-specific immune responses, immune responses to vaccination with Chimerivax-DEN (tetravalent DENV-YFV chimeric vaccine), and vaccine efficacy Identifying the features of protective and pathological immunity to DENV is of importance to advancing vaccine development and utilization.
The immune response to dengue virus can be either beneficial (protect from infection and/or illness) or harmful (increased risk for severe disease). This project will analyze immune responses to dengue virus in individuals with natural exposure and in participants in a vaccine trial in order to understand how the immune response relates to the outcome of infection with dengue virus.
|Moulton, Steven L; Mulligan, Jane; Srikiatkhachorn, Anon et al. (2016) State-of-the-art monitoring in treatment of dengue shock syndrome: a case series. J Med Case Rep 10:233|
|Srikiatkhachorn, Anon; Yoon, In-Kyu (2016) Immune correlates for dengue vaccine development. Expert Rev Vaccines 15:455-65|
|Townsley, E; O'Connor, G; Cosgrove, C et al. (2016) Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells. Clin Exp Immunol 183:419-30|
|Nisalak, Ananda; Clapham, Hannah E; Kalayanarooj, Siripen et al. (2016) Forty Years of Dengue Surveillance at a Tertiary Pediatric Hospital in Bangkok, Thailand, 1973-2012. Am J Trop Med Hyg 94:1342-7|
|Clapham, Hannah E; Rodriguez-Barraquer, Isabel; Azman, Andrew S et al. (2016) Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection. J Infect Dis 213:1428-35|
|Woda, Marcia; Friberg, Heather; Currier, Jeffrey R et al. (2016) Dynamics of Dengue Virus (DENV)-Specific B Cells in the Response to DENV Serotype 1 Infections, Using Flow Cytometry With Labeled Virions. J Infect Dis 214:1001-9|
|Rothman, Alan L; Ennis, Francis A (2016) Dengue Vaccine: The Need, the Challenges, and Progress. J Infect Dis 214:825-7|
|Clapham, Hannah; Cummings, Derek A T; Nisalak, Ananda et al. (2015) Epidemiology of Infant Dengue Cases Illuminates Serotype-Specificity in the Interaction between Immunity and Disease, and Changes in Transmission Dynamics. PLoS Negl Trop Dis 9:e0004262|
|Yoon, In-Kyu (2015) FOCAL DENGUE VIRUS TRANSMISSION IN KAMPHAENG PHET, THAILAND AND IMPLICATIONS FOR MANAGEMENT. Southeast Asian J Trop Med Public Health 46 Suppl 1:17-25|
|Medin, Carey L; Valois, Sierra; Patkar, Chinmay G et al. (2015) A plasmid-based reporter system for live cell imaging of dengue virus infected cells. J Virol Methods 211:55-62|
Showing the most recent 10 out of 114 publications